nChroma halts hepatitis B trial and cuts workforce by about half

nChroma Bio has stopped enrollment and dosing in its only clinical trial, a Phase 1/2 study of CRMA-1001, an experimental liver-directed epigenetic therapy for chronic hepatitis B.

The company is restructuring and laying off about half its workforce while it evaluates strategic options for advancing its programs. It has not publicly given a specific reason for stopping the trial or disclosed the number of employees affected.

Nine participants had received CRMA-1001, according to reporting; they are expected to continue being monitored. The company says its remaining staff will focus on a next-generation, preclinical hepatitis B program.

The move comes less than a year after the trial began and adds to recent financial and development setbacks in the genetic-medicine sector.

Sources:

Layoff Tracker: nChroma halves workforce, BioXcel lets execs go

Recon: FDA approves drugs for four rare diseases; Pfizer signs $2.6B licensing deal in China for in vivo CAR-T

nChroma Bio stops its only clinical study early, lays off 50%

nChroma halves headcount, calls time on trial of potential HBV ‘cure'

Biotech and pharma business news, with a focus on the science, people ...

Andrew Dunn

Boston biotech cuts staff by half, weighs its options

R&D channel feed

Endpoints News

Medical News Today: Surgery Hospital, Cancer America, Disease ...

People channel feed

Andrew Dunn (@AndrewE_Dunn) ...

Boston Business Journal

News & Research – nChroma

Biotech